Is Sotorasib a targeted drug or a chemotherapy drug?

Sotorasib is a targeted therapy drug rather than a traditional chemotherapy drug. Targeted therapy is a relatively new cancer treatment strategy designed to more precisely intervene in the abnormal growth and differentiation of cancer cells, unlike traditional chemotherapy drugs that also have a large toxic effect on normal cells.

The targeting effect of sotoraxib mainly focuses on mutations in the RAS gene. RAS is a protein involved in cell signaling and regulates cell growth and differentiation in normal cells. However, mutations in the RAS gene are a common cancer-related variation that lead to uncontrolled proliferation of cancer cells. By binding to the RAS protein, sotoracib specifically inhibits the activity of the mutated RAS protein, thereby affecting the growth and differentiation of cancer cells.

In contrast, traditional chemotherapy drugs are typically drugs that have broad effects on rapidly dividing cells, including cancer cells and some normal cells. This broad mechanism of action leads to some common side effects of chemotherapy drugs, such as cytotoxicity, anemia, and immune system suppression.

As a targeted therapy drug, sotorasibu focuses more on accurately intervening in the abnormal signaling of cancer cells to reduce the adverse effects on normal cells. This specific therapeutic mechanism is expected to improve the effectiveness of treatment and reduce the burden of side effects on patients during treatment. It is important to note that although targeted therapies have shown significant efficacy in some cases, they are not suitable for all types of cancer. Therefore, patients should discuss it with their doctor in detail before receiving treatment to develop an individualized treatment plan.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.